Arena Pharmaceuticals
MEDICAL AFFAIRS
MENU
IMAGINE

Etrasimod is an investigational, once-daily, oral, selective, S1P receptor modulator designed for engagement of S1P receptors S1P1, S1P4, and S1P5. Arena is evaluating etrasimod for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and eosinophilic esophagitis (EoE).

Etrasimod is an investigational, once-daily, oral, selective, S1P receptor modulator designed for engagement of S1P receptors S1P1, S1P4, and S1P5.
Arena is evaluating etrasimod for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and eosinophilic esophagitis (EoE).

Explore the proposed MOA of etrasimodDiscover current clinical data for etrasimodConnect with Arena at ECCO'22
ECCO=European Crohn’s and Colitis Organisation; GI=gastrointestinal; IBD=inflammatory bowel disease; MOA=mechanism of action; S1P=sphingosine-1-phosphate.
Arena is a clinical stage pharmaceutical company that does not have any medicines or products approved for use by any health authority.

You are now leaving this site and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.

cancelok

THIS INFORMATION IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS

Yes

I AM A U.S. HEALTHCARE/MEDICAL PROFESSIONAL

I acknowledge that I am requesting access to this site, including scientific and educational information about Arena and its research and development programs.

cancel

I AM NOT A U.S. HEALTHCARE/MEDICAL PROFESSIONAL

This site and all materials are intended for U.S. healthcare professionals as a non-promotional resource for medical and scientific information and non-certified medical education purposes only.
© 2022 Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals and Arena are registered service marks of Arena Pharmaceuticals, Inc.
All Rights Reserved. 12/2021: MRC--DHF-0001